Literature DB >> 16236265

Monoacetylcurcumin: a new inhibitor of eukaryotic DNA polymerase lambda and a new ligand for inhibitor-affinity chromatography.

Yoshiyuki Mizushina1, Tomomi Ishidoh, Toshifumi Takeuchi, Noriko Shimazaki, Osamu Koiwai, Kouji Kuramochi, Susumu Kobayashi, Fumio Sugawara, Kengo Sakaguchi, Hiromi Yoshida.   

Abstract

We previously reported that a phenolic compound, curcumin (diferuloylmethane), was a selective inhibitor of DNA polymerase lambda (pol lambda) in vitro [Y. Mizushina, M. Hirota, C. Murakami, T. Ishidoh, S. Kamisuki, N. Shimazaki, M. Takemura, M. Perpelescu, M. Suzuki, H. Yoshida, F. Sugawara, O. Koiwai, K. Sakaguchi, Some anti-chronic inflammatory compounds are DNA polymerase lambda-specific inhibitors, Biochem. Pharmacol. 66 (2003) 1935-1944.]. We also found that monoacetylcurcumin ([1E,4Z,6E]-7-(4''-acetoxy-3''-methoxyphenyl)-5-hydroxy-1-(4'-hydroxy-3'-methoxyphenyl)hepta-1,4,6-trien-3-on), a chemically synthesized derivative of curcumin, was a stronger pol lambda inhibitor than curcumin, achieving 50% inhibition at a concentration of 3.9microM. Monoacetylcurcumin did not influence the activities of replicative pols such as alpha, delta, and epsilon, and showed no effect even on the activity of pol beta, the three-dimensional structure of which is thought to be highly similar to that of pol lambda. The compound-induced inhibition of pol lambda activity was non-competitive with respect to both the DNA template-primer and the dNTP substrate. Monoacetylcurcumin did not inhibit the activity of the C-terminal catalytic domain of pol lambda including the pol beta-like core, in which the BRCT motif was deleted. The compound did not influence the activities of prokaryotic pols or other mammalian DNA metabolizing enzymes such as calf primase of pol alpha, calf terminal deoxynucleotidyl transferase, human telomerase, human immunodeficiency virus type-1 reverse transcriptase, T7 RNA polymerase, T4 polynucleotide kinase, and bovine deoxyribonuclease I. Therefore, we concluded that monoacetylcurcumin is a selective inhibitor of pol lambda and could be used as a chromatographic ligand to purify pol lambda. We then made a monoacetylcurcumin-conjugated column with epoxy-activated Sepharose 6B. In the column, pol lambda of full length was selectively adsorbed and eluted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16236265     DOI: 10.1016/j.bbrc.2005.10.005

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

Review 1.  Perspectives on chemopreventive and therapeutic potential of curcumin analogs in medicinal chemistry.

Authors:  Subhash Padhye; Deepak Chavan; Shubhangini Pandey; Jyoti Deshpande; K Venkateswara Swamy; Fazlul H Sarkar
Journal:  Mini Rev Med Chem       Date:  2010-05       Impact factor: 3.862

2.  Cancer-linked targets modulated by curcumin.

Authors:  Noor Hasima; Bharat B Aggarwal
Journal:  Int J Biochem Mol Biol       Date:  2012-12-24

3.  Effects of intermediates between vitamins K(2) and K(3) on mammalian DNA polymerase inhibition and anti-inflammatory activity.

Authors:  Yoshiyuki Mizushina; Jun Maeda; Yasuhiro Irino; Masayuki Nishida; Shin Nishiumi; Yasuyuki Kondo; Kazuyuki Nishio; Kouji Kuramochi; Kazunori Tsubaki; Isoko Kuriyama; Takeshi Azuma; Hiromi Yoshida; Masaru Yoshida
Journal:  Int J Mol Sci       Date:  2011-02-10       Impact factor: 5.923

4.  Inhibitory effects of glycyrrhetinic Acid on DNA polymerase and inflammatory activities.

Authors:  Tsukasa Ishida; Yoshiyuki Mizushina; Saori Yagi; Yasuhiro Irino; Shin Nishiumi; Ikuya Miki; Yasuyuki Kondo; Shigeto Mizuno; Hiromi Yoshida; Takeshi Azuma; Masaru Yoshida
Journal:  Evid Based Complement Alternat Med       Date:  2011-07-14       Impact factor: 2.629

5.  Synergic effect of curcumin and its structural analogue (Monoacetylcurcumin) on anti-influenza virus infection.

Authors:  Sarah M Richart; Yi-Lin Li; Yoshiyuki Mizushina; Yuan-Yen Chang; Tse-Yu Chung; Guan-Heng Chen; Jason Tze-Cheng Tzen; Kak-Shan Shia; Wei-Li Hsu
Journal:  J Food Drug Anal       Date:  2018-02-02       Impact factor: 6.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.